New York, January 10, 2026, 18:35 EST — Market closed
- Shares of NovaBay Pharmaceuticals surged roughly 103% to close Friday at $19.16
- This surge arrives as investors re-examine the company’s asset sales and wind-down language in its filings
- Attention shifts to Monday’s reopening and the upcoming earnings report scheduled next
Shares of NovaBay Pharmaceuticals Inc soared on Friday, closing up roughly 103% at $19.16. Over 10 million shares changed hands, market data showed.
NovaBay is back on momentum screens before the next U.S. session, trading in a price range unseen for over a year.
Why it matters now: NovaBay’s size means its price often moves on volume, not news. When that shift hits before a weekend, the following open becomes a gauge of who’s left to buy.
The stock moved between $9.69 and $19.95 in regular trading, then was last seen near $20.50 after hours on Friday, data showed.
NovaBay revealed in its latest quarterly filing that it sold its main “Avenova” trademark to PRN Physician Recommended Nutriceuticals, with the deal effective Jan. 17, 2025. The company also offloaded the “PhaseOne” and “NeutroPhase” U.S. trademarks, effective Jan. 8, 2025. The board decided the best path to unlock remaining value is pursuing dissolution and putting that plan to shareholders. At the end of June 2025, NovaBay reported $5.3 million in cash and equivalents, and as of Aug. 12, 2025, it had 5.82 million shares outstanding. SEC
Last August, NovaBay announced a one-time special cash dividend of $0.80 per share. CEO David Lazar described it as “reflecting our commitment to creating and returning value directly to our stockholders.” BioSpace
A separate insider filing detailed pre-funded warrants tied to an investor deal, which can be exercised for common shares after Jan. 1, 2026, pending shareholder approval. These pre-funded warrants let buyers pay nearly the full price upfront and convert to shares at a later date.
That very setup driving steep rallies can just as easily reverse. A change in outlook on a wind-down, adjustments to capital structure, or even straightforward profit-taking could slam a thin tape suddenly and sharply.
Markets reopen Monday, Jan. 12, with traders eyeing if volume holds steady and any fresh company disclosures emerge following last week’s jump. According to TipRanks, NovaBay’s next earnings report is due March 26, after the close.
Related articles: Pharmaceuticals
